Physician
Internal Medicine
Dr. Marina Konopleva, MD
|
|
Give Review
Doctor Marina Konopleva, MD is an expert in the field of Internal Medicine. She has 1 awards "Elected Member". Marina Konopleva is a published doctor as well. She has 101 publications published. The latest was: Ligation of cell surface CD38 protein with agonistic monoclonal antibody induces a cell growth signal in myeloid leukemia cells. Doctor Marina Konopleva, MD accepts Medicare.
Publications
- Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients.
- Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents.
- A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome.
- Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia.
- De Novo MYC and BCL2 Double-hit B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) in Pediatric and Young Adult Patients Associated With Poor Prognosis.
- Sorafenib and novel multikinase inhibitors in AML.
- Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade.
- Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase...
- Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes.
- PKR inhibits the DNA damage response, and is associated with poor survival in AML and accelerated leukemia in NHD13 mice.
- Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells.
- Secondary Mutations as Mediators of Resistance to Targeted Therapy in Leukemia.
- Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
- mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells.
- Tyrosine kinase inhibitors induce mesenchymal stem cell-mediated resistance in BCR-ABL+ acute lymphoblastic leukemia.
- A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed / Refractory Acute Lymphoblastic Leukemia.
- Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia.
- A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults.
- Phase I/II Trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.
- Similar Transplantation Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Haploidentical versus 10/10 Human Leukocyte Antigen-Matched Unre...
- BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia.
- Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).
- SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid...
- The protein phosphatase 2A regulatory subunit B55α is a modulator of signaling and microRNA expression in acute myeloid leukemia cells.
- Activity of SL-401, a targeted therapy directed to the interleukin-3 receptor, in patients with blastic plasmacytoid dendritic cell neoplasm.
- Evaluation of Apoptosis Induction by Concomitant Inhibition of MEK, mTOR, and Bcl-2 in Human Acute Myeloid Leukemia Cells.
- Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.
- FOXP3 is a direct target of miR15a/16 in umbilical cord blood regulatory T cells.
- Advances in understanding the leukaemia microenvironment.
- Reversal of Acquired Drug Resistance in FLT3-mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies.
- Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance.
- Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia.
- Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia.
- Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents.
- Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease.
- Selective BCL-2 Inhibition by ABT-199 Causes On Target Cell Death in Acute Myeloid Leukemia.
- BH3 Profiling Discriminates Response to Cytarabine-Based Treatment of Acute Myelogenous Leukemia.
- BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells.
- The combination of Hyper-CVAD plus nelarabine as frontline therapy in adult T cell acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (LL)-MD Anderson c...
- Targeting connective tissue growth factor (CTGF) in acute lymphoblastic leukemia preclinical models: anti-CTGF monoclonal antibody attenuates leukemia growth.
- CXC Chemokine Receptor 4 Expression, CXC Chemokine Receptor 4 Activation, and Wild-Type Nucleophosmin Are Independently Associated With Unfavorable Prognosis in Patien...
- Outcome After Failure of Second Generation Tyrosine Kinase Inhibitors Treatment As First-line Therapy for Patients With Chronic Myeloid Leukemia.
- Connective tissue growth factor regulates adipocyte differentiation of mesenchymal stromal cells and facilitates leukemia bone marrow engraftment.
- Modest activity of pomalidomide in patients with myelofibrosis and significant anemia.
- Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤ 60 years with newly diagnosed acute myeloid leukemia (AML).
- HDAC inhibition by SNDX-275 (Entinostat) restores expression of silenced leukemia-associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in ...
- Phase II study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.
- The CXCR4 Antagonist AMD3465 Regulates Oncogenic Signaling and Invasiveness In Vitro and Prevents Breast Cancer Growth and Metastasis In Vivo.
- Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia.
- Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells.
- Regulation of HIF-1α signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment.
- Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML under conditions mimicking the bone marrow microenvironment.
- Small gene, big number, many effects.
- Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplant.
- Laser nanothermolysis of human leukemia cells using functionalized plasmonic nanoparticles.
- Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells.
- A Randomized Controlled Trial of an Intensive Insulin Regimen in Patients With Hyperglycemic Acute Lymphoblastic Leukemia.
- Human extramedullary bone marrow in mice: a novel in vivo model of genetically controlled hematopoietic microenvironment.
- Activation of apoptosis signaling eliminates CD34(+) progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors.
- MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.
- Leukemia stem cells and microenvironment: biology and therapeutic targeting.
- Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.
- The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML.
- Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma.
- Bcl2 phosphorylation and active PKC alpha are associated with poor survival in AML.
- Apoptosis effector mechanisms: a requiem performed in different keys.
- Synthetic triterpenoids have cytotoxicity in pediatric acute lymphoblastic leukemia cell lines but cytotoxicity is independent of induced ceramide increase in MOLT-4 c...
- Antidiabetic therapies affect risk of pancreatic cancer.
- Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor.
- Mitochondrial uncoupling and the reprograming of intermediary metabolism in leukemia cells.
- TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment.
- ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies.
- XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38- cells in a phase 1/2 study of patients with relaps...
- Phase I study of sorafenib in patients with refractory or relapsed acute leukemias.
- Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase.
- Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.
- Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vi...
- Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.
- Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
- Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype.
- Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
- Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other a...
- Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway.
- Low expression of PP2A regulatory subunit B55α is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients.
- Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia.
- Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.
- Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias.
- Targeting the leukemia microenvironment.
- Independent prognostic significance of day 21 cytogenetic findings in newly-diagnosed acute myeloid leukemia or refractory anemia with excess blasts.
- Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins.
- Guggulsterones induce apoptosis and differentiation in acute myeloid leukemia: identification of isomer-specific antileukemic activities of the pregnadienedione struct...
- Blockade of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase and murine double minute synergistically induces Apoptosis in acute myeloid l...
- Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia.
- The anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cells.
- The novel triterpenoid CDDO-Me suppresses MAPK pathways and promotes p38 activation in acute myeloid leukemia cells.
- Ligation of cell surface CD38 protein with agonistic monoclonal antibody induces a cell growth signal in myeloid leukemia cells.
- Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelo...
- Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia.
- Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.
- Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid.
Schools
Ip Pavlov Higher Medical Institute
Doctors Specialties
- Internal Medicine
Accepted Insurances
Awards
- Elected Member
Education
-
Texas Tech University at Lubbock -
St Petersburg Medical State Academy
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1518063486 | |
| NPPES Provider LastName | KONOPLEVA | |
| NPPES Provider FirstName | MARINA | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 355.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 12.0 | |
| Percent Opioid Claims | 3.38 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1518063486 |
| Last Name Of The Provider | KONOPLEVA |
| First Name Of The Provider | MARINA |
| View All |
Similar Doctors
|
|
Dr. Adarsh M. Hiremath, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Barkat K. Bandeali, DO |
|
|
Dr. Lauren A. Byers, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shazia F. Ali, MD |
|
|
Dr. Natalie M. Dang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Risheng Xu, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shilpa Singh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ralf B. Lukner, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Mark A. Farnie, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Steven S. Goldstein, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Harish N. Thakkar, MD
This Doctor is OpenDoctor Recommended.
|